ABNOM
☆ AI Dermatology — Free Service
Германаас гаргасан 2022 оны Stiftung Warentest-ийн үр дүнгээс үзэхэд ModelDerm-ийн хэрэглэгчдийн сэтгэл ханамж нь төлбөртэй телемедицинийн зөвлөгөө авахаас арай доогуур байв.
Германаас гаргасан 2022 оны Stiftung Warentest-ийн үр дүнгээс үзэхэд ModelDerm-ийн хэрэглэгчдийн сэтгэл ханамж нь төлбөртэй телемедицинийн зөвлөгөө авахаас арай доогуур байв.
relevance score : -100.0%
ReferencesQ‑switched Nd:YAG лазер нь Отагийн невус болон үүнтэй төстэй эмгэгийг үр дүнтэй эмчилдэг. Бид high‑fluence 1064 nm Q‑switched Nd:YAG лазер нь ер бусын газар нутаг дахь монгол толбо дээр арьсыг цайруулахгүйгээр хэр сайн ажилладаг талаар судалгаа хийсэн. Бид эдгээр толботой 61 өвчтөнийг судалж, нийт 70 гэмтлийг шалгасан. Гэмтлийн тэн хагасыг лазераар эмчилсэн, заримыг нь харьцуулахын тулд эмчлэхгүй орхисон. Бид меланины түвшинг хэмжих масштаб болон Mexameter® хэмээх төхөөрөмжийг ашиглан үр дүнг үнэлсэн. Эмчилгээний бүлэгт өвчтөнүүдийг дунджаар 14 сар, ажиглалтын бүлэгт 18 сар ажигласан. Судалгааны төгсгөлд эмчилсэн болон эмчилгээ хийгээгүй бүлгүүдийн хооронд масштабын оноо болон меланины түвшинд мэдэгдэхүйц ялгаа байгааг олж мэдсэн; лазераар эмчилсэн бүлэг илүү сайн үр дүнг харуулсан. High‑fluence Q‑switched Nd:YAG лазер нь арьсыг цайруулахгүйгээр эдгээр ер бусын монгол толбыг эмчлэхэд үр дүнтэй, аюулгүй гэдгийг баталсан.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Бид тусгай лазер эмчилгээг ABNOM‑д хэрэглэх үр дүн, аюулгүй байдлыг судалж, ямар хүчин зүйлүүд ажиллахад нөлөөлдөгийг тодорхойлсон. ABNOM‑тэй 2‑9 удаа лазер эмчилгээ хийлгэсэн 110 өвчтөнийг судалсан. Эмчилгээ удаан үргэлжлэх тусам илүү үр дүнтэй байсан ч өндөр настай өвчтөнүүдэд тийм ч сайн биш болохыг бид олж мэдсэн. Энэ нь цайвар арьстай (III төрөл) болон жижиг өртсөн хэсгүүдтэй (10 см²‑аас бага) өвчтөнүүдэд илүү сайн ажилласан. ABNOM‑тай хамт мелазма өвчтэй байсан нь эмчилгээг үр дүнгүй болгосон. Нөлөөлөлд өртсөн хэсгүүдийн өнгө, тоо ялгаагүй байсан. Өвчтөнүүдийн 10 орчим хувь нь эмчилгээний дараа хар толботой болсон. Эрт олон удаагийн эмчилгээ сайн үр дүнд хүрсэн. Харанхуй арьстай, хар толботой өндөр настай өвчтөнүүд эмчилгээний дараа хар толбо үүсэх магадлал өндөр байдаг. ABNOM болон меласматай өвчтөнүүдэд меласмаг хүндрүүлэхгүй байх 위해 бага энергитэй лазер ашиглах нь зөв.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Эмчилгээ
Цайруулах бодис ховорхон тусалдаг. Меласмаас ялгаатай нь, ABNOM-ийг лазераар эмчлэх замаар сайжруулж, дахилтгүйгээр арилгах боломжтой. ABNOM‑ийг эмчлэхийн тулд лазер эмчилгээг 10‑20 удаа хийж болно.
#QS1064 laser